Your lung cancer care has an entire team behind it at the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus, says radiation… Read More »Which health professionals will be on my lung cancer care team?
Knowing your stage of cancer is essential to helping your treatment team figure out the best approach to tackling your lung cancer, says Russell K.… Read More »What drives your treatment for lung cancer other than the stage you’re in?
Understanding the stage of lung cancer disease is vital in understanding how best to treat a patient, says Russell K. Hales, M.D. Hales, who is… Read More »How your lung cancer stage affects the treatment you’ll receive: Know your cancer roadmap
Medical teams at the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus “have to fight two battles in order to control the… Read More »“We fight two battles to control lung cancer”
“When we think about lung cancer, we usually think of it being associated with people who smoke,” says Russell K. Hales, M.D. “But, in fact,… Read More »Why is lung cancer so difficult to treat?
There is good news today for lung cancer patients. The FDA has announced that it has approved expansion of the immunotherapy drug nivolumab (Opdivo) for… Read More »Immunotherapy drug approved for lung cancer
*This post was written by Marie Borsellino, B.S.N., R.N., O.C.N., oncology nurse navigator for the Managing Cancer at Work Program. Cigarette smoking is the most… Read More »Do you have any Lung Cancer Risk Factors?
Recent news of the full results of the National Lung Screening Trial (NLST) published in the New England Journal of Medicine underscores the heavy toll… Read More »Lung Cancer: Still the Top Cancer Killer
Three stories top the list of major developments in cancer research during the past month. Listen to these topics discussed in the most recent Cancer News Review podcast.
First, to treat or not to treat is the question for low-risk prostate cancer. Whether to give aggressive treatments for low-risk cancer contained within the prostate is a controversy that many experts in the field still debate. Prostate cancer expert and Kimmel Cancer Center director William Nelson reviews a study analyzing how treatment decisions for these cancers are made and how quality of life expectations are communicated. He says the current problem is that screening, which has helped decrease mortality from prostate cancer, has identified some men who could live their entire lives with prostate cancer but die of other causes. He believes there are certain groups of men who should consider active surveillance programs to carefully monitor low-risk, organ-confined prostate cancer.